Zyklophin
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C65H96N20O13 |
Molar mass | 1365.610 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Zyklophin is a semisynthetic peptide derived from dynorphin A and a highly selective antagonist of the κ-opioid receptor (KOR).[1][2] It is systemically-active, displaying good metabolic stability and blood-brain-barrier penetration.[2] Similarly to other KOR antagonists, it has been shown to block stress-induced reinstatement of cocaine-seeking in animals.[2] The drug is currently experimental, and thus cannot be considered safe for consumption or usage.
See also
References
- ↑ Patkar KA, Yan X, Murray TF, Aldrich JV (July 2005). "[Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist". J. Med. Chem. 48 (14): 4500–3. doi:10.1021/jm050105i. PMID 15999987.
- 1 2 3 Aldrich JV, Patkar KA, McLaughlin JP (October 2009). "Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action". Proc. Natl. Acad. Sci. U.S.A. 106 (43): 18396–401. doi:10.1073/pnas.0910180106. PMC 2775281. PMID 19841255.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.